146 related articles for article (PubMed ID: 11495048)
1. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea.
Paik YH; Chung HY; Ryu WS; Lee KS; Lee JS; Kim JH; Lee CK; Chon CY; Moon YM; Han KH
J Hepatol; 2001 Jul; 35(1):92-8. PubMed ID: 11495048
[TBL] [Abstract][Full Text] [Related]
2. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
3. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
[TBL] [Abstract][Full Text] [Related]
4. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
[TBL] [Abstract][Full Text] [Related]
5. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.
Kirishima T; Okanoue T; Daimon Y; Itoh Y; Nakamura H; Morita A; Toyama T; Minami M
J Hepatol; 2002 Aug; 37(2):259-65. PubMed ID: 12127432
[TBL] [Abstract][Full Text] [Related]
6. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
7. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
Yang DH; Liang WF; Xie YJ; Zhao NF; Fan J
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
[TBL] [Abstract][Full Text] [Related]
8. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
[TBL] [Abstract][Full Text] [Related]
9. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
10. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
[TBL] [Abstract][Full Text] [Related]
11. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection.
Heo J; Cho M; Kim HH; Shin YM; Jang HJ; Park HK; Kim CM; Kim GH; Kang DH; Song GA; Yang US
J Korean Med Sci; 2004 Aug; 19(4):541-6. PubMed ID: 15308845
[TBL] [Abstract][Full Text] [Related]
12. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
Mori K; Minami M; Kirishima T; Kunimoto K; Okita M; Nakayama M; Makiyama A; Yamaoka J; Nakajima T; Yasui K; Itoh Y; Okanoue T
Intervirology; 2006; 49(5):274-80. PubMed ID: 16714856
[TBL] [Abstract][Full Text] [Related]
13. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers.
Kobayashi S; Ide T; Sata M
J Hepatol; 2001 Apr; 34(4):584-6. PubMed ID: 11394659
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine therapy for Japanese patients with cirrhosis B.
Okanoue T; Mori K; Kirishima T; Kunimoto K; Yasui K; Itoh Y; Minami M
Intervirology; 2003; 46(6):394-9. PubMed ID: 14688458
[TBL] [Abstract][Full Text] [Related]
15. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
Hosseini SY; Sabahi F; Amini-Bavil-Olyaee S; Alavian SM; Merat S
J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
[TBL] [Abstract][Full Text] [Related]
16. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
17. YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation.
Pei F; Ning JY; You JF; Yang JP; Zheng J
World J Gastroenterol; 2005 May; 11(18):2714-9. PubMed ID: 15884109
[TBL] [Abstract][Full Text] [Related]
18. YMDD mutations and genotypes of hepatitis B virus in northern China.
Li D; Gu HX; Zhang SY; Zhong ZH; Zhuang M; Hattori T
Jpn J Infect Dis; 2006 Feb; 59(1):42-5. PubMed ID: 16495633
[TBL] [Abstract][Full Text] [Related]
19. Rare quasispecies in the YMDD motif of hepatitis B virus detected by polymerase chain reaction with peptide nucleic acid clamping.
Ohishi W; Chayama K
Intervirology; 2003; 46(6):355-61. PubMed ID: 14688452
[TBL] [Abstract][Full Text] [Related]
20. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
